retatrutide type 2 diabetes trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a New clinical trial results show

(2023, The Lancet) Type 2 Diabetes Trial Study Design: Randomized, double-blind, placebo- and active-controlled Phase 2 trial in adults with type 2 diabetes

[DOI] [PubMed] [Google Scholar] 99.Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, et al

Most clinical studies tracked fat loss for 48 weeks, with the most optimal effects at the end of treatment

Appetite, hormones, blood sugar, sleep, stress, metabolism, and fat stored around the organs can all affect how the body responds to diet and lifestyle changes

Others feel more comfortable with oral medication taken each day

Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, et al